Ixed

Human Coagulation Factor IX, the active ingredient in Ixed, is a coagulation factor presented as an injectable solution for intravenous use. It treats hemophilia B (Factor IX deficiency) by providing the missing clotting protein to patients who require factor replacement therapy.

GNH USA supplies Ixed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ixed is a recombinant coagulation factor used within the intrinsic pathway to manage bleeding disorders associated with Factor IX deficiency.

Hemophilia B: restores deficient Factor IX levels to achieve effective hemostasis. Surgical prophylaxis: maintains therapeutic Factor IX activity during operative procedures to prevent excessive bleeding. Trauma management: provides rapid factor replacement to control acute bleeding episodes in patients with known Factor IX deficiency.

Ixed may be associated with a range of infusion‑related and immunologic reactions.

Common Side Effects: - Infusion site erythema or pain - Mild fever or chills - Headache - Nausea - Arthralgia - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Development of neutralizing inhibitors (antibodies) to Factor IX - Thrombotic events, including deep‑vein thrombosis - Viral transmission risk from biologic product - Severe hemolysis - Disseminated intravascular coagulation (rare)

Prior to initiating therapy, clinicians should assess individual patient risk factors and monitor treatment response.

Dose individualization: adjust based on measured Factor IX activity and clinical response. Inhibitor screening: test for anti‑Factor IX antibodies before and during therapy. Thrombosis risk: use caution in patients with a history of thromboembolic disease. Allergy assessment: avoid in individuals with known hypersensitivity to the product or its excipients. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Factor IX replacement therapy can interact with agents that affect coagulation balance.

Major Interactions (Avoid): - Concomitant use of pro‑coagulant concentrates (e.g., activated prothrombin complex) may increase thrombosis risk. - Co‑administration with anticoagulants such as warfarin or direct oral anticoagulants can diminish therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs may alter inhibitor development; monitor Factor IX activity. - Certain vaccines may provoke immune responses that affect inhibitor formation; observe for adverse reactions. - Antibiotics that impact liver function could theoretically influence protein metabolism; assess clinical status.